4.8 Article

Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia

Journal

NATURE GENETICS
Volume 42, Issue 6, Pages 530-U84

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/ng.587

Keywords

-

Funding

  1. K.U. Leuven
  2. FWO-Vlaanderen [G.0287.07]
  3. Foundation against Cancer [SCIE2006-34]
  4. European Research Council
  5. European Hematology Association
  6. Federal Office for Scientific, Technical and Cultural Affairs, Belgium
  7. French program Carte d'Identite des Tumeurs
  8. Canceropole d'Ile de France
  9. New York Community Trust
  10. National Institutes of Health [CA120196, CA129382]

Ask authors/readers for more resources

PTPN2 (protein tyrosine phosphatase non-receptor type 2, also known as TC-PTP) is a cytosolic tyrosine phosphatase that functions as a negative regulator of a variety of tyrosine kinases and other signaling proteins(1-3). In agreement with its role in the regulation of the immune system, PTPN2 was identified as a susceptibility locus for autoimmune diseases(4,5). In this work, we describe the identification of focal deletions of PTPN2 in human T-cell acute lymphoblastic leukemia (T-ALL). Deletion of PTPN2 was specifically found in T-ALLs with aberrant expression of the TLX1 transcription factor oncogene(6), including four cases also expressing the NUP214-ABL1 tyrosine kinase(7). Knockdown of PTPN2 increased the proliferation and cytokine sensitivity of T-ALL cells. In addition, PTPN2 was identified as a negative regulator of NUP214-ABL1 kinase activity. Our study provides genetic and functional evidence for a tumor suppressor role of PTPN2 and suggests that expression of PTPN2 may modulate response to treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available